1-(4-(5-phenylimidazo[1,2-a]pyrazin-6-yl)phenyl)cyclobutanamine hydrochloride | 1357270-61-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 英文名称: 1-(4-(5-phenylimidazo[1,2-a]pyrazin-6-yl)phenyl)cyclobutanamine hydrochloride
• 英文别名: 1-[4-(5-Phenylimidazo[1,2-a]pyrazin-6-yl)phenyl]cyclobutan-1-amine;hydrochloride
• CAS: 1357270-61-1
• 化学式: C₂₂H₂₀N₄*ClH
• 分子量: 376.889
• InChiKey: KQGZREBPOJKVIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.82
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  56.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  tert-butyl 1-(4-(5-amino-3-phenylpyrazin-2-yl)phenyl)cyclobutylcarbamate 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 1-(4-(5-phenylimidazo[1,2-a]pyrazin-6-yl)phenyl)cyclobutanamine hydrochloride
  参考文献：
  名称：

  Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT

  摘要：

  Wide-ranging exploration of potential replacements for a quinoline-based inhibitor of activation of AKT kinase led to number of alternative, novel scaffolds with potentially improved potency and physicochemical properties. Examples showed predictable DMPK properties, and one such compound demonstrated pharmacodynamic knockdown of phosphorylation of AKT and downstream biomarkers in vivo and inhibition of tumor growth in a breast cancer xenograft model.

  DOI：

  10.1021/jm201394e

文献信息

• Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT
  作者：Jason G. Kettle、Simon Brown、Claire Crafter、Barry R. Davies、Phillippa Dudley、Gary Fairley、Paul Faulder、Shaun Fillery、Hannah Greenwood、Janet Hawkins、Michael James、Keith Johnson、Clare D. Lane、Martin Pass、Jennifer H. Pink、Helen Plant、Sabina C. Cosulich

  DOI：10.1021/jm201394e

  日期：2012.2.9

  Wide-ranging exploration of potential replacements for a quinoline-based inhibitor of activation of AKT kinase led to number of alternative, novel scaffolds with potentially improved potency and physicochemical properties. Examples showed predictable DMPK properties, and one such compound demonstrated pharmacodynamic knockdown of phosphorylation of AKT and downstream biomarkers in vivo and inhibition of tumor growth in a breast cancer xenograft model.